Physician profile
Lee Michael Perry
NPI 1225252125
$9,932.97
in general payments reported to CMS, 2019-2025
38 companies · $1,959 in 2025
The $1,959 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,375 · 2020: $762 · 2021: $1,437 · 2022: $1,275 · 2023: $1,505 · 2024: $1,620 · 2025: $1,959.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,978 · Education: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,977.95 |
| Education | $106.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $1,382.26 | 2019-2025 | Haegarda, Hizentra, Andembry |
| Glaxosmithkline, LLC. | $1,170.68 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Regeneron Healthcare Solutions, INC. | $1,121.09 | 2019-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $1,019.89 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Pfizer INC. | $690.77 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $592.46 | 2020-2025 | Takhzyro, Hyqvia, Cuvitru |
| Genzyme Corporation | $584.47 | 2020-2025 | |
| Grifols USA, LLC | $376.29 | 2019-2025 | Prolastin-C Liquid, Xembify |
| Genentech USA, INC. | $352.37 | 2019-2024 | Xolair |
| Octapharma USA, INC. | $321.39 | 2021 | |
| Shire North American Group INC | $243.72 | 2019 | |
| Amgen INC. | $234.71 | 2021-2025 | Tezspire |
| Optinose US, INC. | $211.10 | 2019-2025 | |
| Pharming Healthcare, INC. | $205.30 | 2021-2025 | Ruconest |
| Ars Pharmaceuticals Operations, INC. | $200.65 | 2025 | Neffy |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lee Perry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.